overcast
Daiichi Sankyo Co. said Monday that her mNNA-based vaccine candidate COVID-19 had decided to be included in a drug discovery program through the Japanese Agency for Medical Research and Development.
The vaccine, known as DS-5670, was decided by the circular timing of the AMED coVID-19 curriculum. Daiichi Sankyo aims to publicize clinical studies of circular vaccine in March 2021 in collaboration with the University of Tokyo.
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. today so that we can continue to provide you with up-to-date and detailed data on Japan.
The Japan Times LTD. All rights are reserved.